Press Release

Cipla announces Q4 FY1415 Audited Consolidated Financial Results

Mumbai, India, 29th May 2015: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Audited Consolidated Financial Results for the quarter ended March 31, 2015 (Q4).

Key Financial & Performance Highlights Q4 FY1415 vis-a-vis Q4 FY1314:
(Current year figures include the relevant results of Cipla’s subsidiaries from the date they became subsidiary of the company and therefore the corresponding figures for the previous period are not comparable).

- Income from operations grew by 22.1% to Rs. 3,093 cr, up from Rs. 2,533 cr
- EBITDA grew by 24% to Rs. 508 cr, up from Rs. 409 cr
- Profit after tax flat at Rs. 260 cr for Q4 FY1415 as compared to Q4 FY1314

![Revenue and Profit Movement](image)

![Geographic Sales Mix](image)

![Business Mix](image)
Profit & Loss Highlights:

- Material cost is at 37.5% of income from operations in Q4 FY1415 as compared to 39.6% in Q4 FY1314
- EBIDTA as % of income from operations increased to 16.4% in Q4 FY1415 from 16.2% in Q4 FY1314
- Profit after tax flat at Rs. 260 for Q4 FY1415 as compared to Q4 FY1314

Performance Review:

Domestic business:

- Domestic sales grew by 20.7% to Rs. 1,086 cr during Q4 FY1415, up from Rs. 900 cr during Q4 FY1314
- The growth in domestic sales was largely on account of growth in Respiratory, Anti-infectives, Cardiac and Gastro Intestinal therapies

International business:

- Exports of formulations increased by 29.7% to Rs. 1,690 cr during Q4 FY1415, from Rs. 1,303 cr during Q4 FY1314
- Exports of APIs declined to Rs. 205 cr during Q4 FY1415, from Rs. 240 cr during Q4 FY1314.

About Cipla:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Cipla’s portfolio includes over 1500 products in various therapeutic categories with one quality standard globally. Cipla’s turnover in 2013/14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Media Contacts:

Investor Relations
Anant Atal
Contact No.: 022 – 24826450
E-Mail: anant.atal@cipla.com

Corporate Communications
Pallavi Golar
Contact No.: +91 9833641788
E-Mail: pallavi.golar@cipla.com